CN108136209A - 用于改进nrf2激活的组合物和其使用方法 - Google Patents

用于改进nrf2激活的组合物和其使用方法 Download PDF

Info

Publication number
CN108136209A
CN108136209A CN201680050947.0A CN201680050947A CN108136209A CN 108136209 A CN108136209 A CN 108136209A CN 201680050947 A CN201680050947 A CN 201680050947A CN 108136209 A CN108136209 A CN 108136209A
Authority
CN
China
Prior art keywords
extract
luteolin
composition
rosemary
specified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680050947.0A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁克斯·迈克尔·海伯特松
乔·米尔顿·麦考德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Path Biology Science Co Ltd
Original Assignee
Path Biology Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Path Biology Science Co Ltd filed Critical Path Biology Science Co Ltd
Priority to CN202510745791.9A priority Critical patent/CN120754114A/zh
Publication of CN108136209A publication Critical patent/CN108136209A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201680050947.0A 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法 Pending CN108136209A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510745791.9A CN120754114A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US62/214,175 2015-09-03
US201662355810P 2016-06-28 2016-06-28
US62/355,810 2016-06-28
PCT/US2016/050292 WO2017041054A1 (en) 2015-09-03 2016-09-02 Compositions for improved nrf2 activation and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510745791.9A Division CN120754114A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Publications (1)

Publication Number Publication Date
CN108136209A true CN108136209A (zh) 2018-06-08

Family

ID=58188643

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680050947.0A Pending CN108136209A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法
CN202510745791.9A Pending CN120754114A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510745791.9A Pending CN120754114A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Country Status (9)

Country Link
US (1) US11413269B2 (https=)
JP (1) JP6901787B2 (https=)
CN (2) CN108136209A (https=)
CL (1) CL2018000573A1 (https=)
CO (1) CO2018003454A2 (https=)
HK (1) HK1256480A1 (https=)
MX (2) MX394479B (https=)
PE (1) PE20190380A1 (https=)
WO (1) WO2017041054A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354916A1 (en) * 2015-09-03 2022-11-10 Pathways Bioscience, Llc Compositions for improved nrf2 activation and methods of their use
IL264076B (en) * 2016-07-11 2022-07-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Treatment of follicular tonsillitis using plant extracts containing carnosic acid
JP2020517594A (ja) * 2017-04-27 2020-06-18 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 大気汚染関連疾患から防護するためのウィザニア・ソムニフェラ抽出物の使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304823A1 (en) * 2006-04-03 2009-12-10 Nestec S.A. Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same
US20140271944A1 (en) * 2004-03-23 2014-09-18 Lifeline Nutraceuticals Compositions for Alleviating Inflammation and Oxidative Stress in a Mammal

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
EP2265126A4 (en) 2008-03-10 2011-06-29 Univ Louisville Res Found PROCESS AND COMPOSITIONS FOR THE CONTROLLED DELIVERY OF PHYTOCHEMICALS
JP5608646B2 (ja) 2008-07-31 2014-10-15 シャクリー コーポレーション 向上した抗酸化活性を有するマスカダイン組成物
JP2011057654A (ja) 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
EP2515925A4 (en) 2009-12-24 2014-05-21 Univ Mcgill COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THE HEALTH EFFECTS CAUSED BY THE ENVIRONMENT
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
MX347457B (es) * 2012-01-16 2017-04-27 Héctor De Jesús Velez-Rivera Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares.
JP2013209351A (ja) * 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) 2013-03-14 2014-09-25 Walley Darlene Topical products
WO2015008301A1 (en) * 2013-07-17 2015-01-22 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271944A1 (en) * 2004-03-23 2014-09-18 Lifeline Nutraceuticals Compositions for Alleviating Inflammation and Oxidative Stress in a Mammal
US20090304823A1 (en) * 2006-04-03 2009-12-10 Nestec S.A. Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same

Also Published As

Publication number Publication date
US11413269B2 (en) 2022-08-16
JP2018529763A (ja) 2018-10-11
MX2018002743A (es) 2018-06-06
CO2018003454A2 (es) 2018-08-31
MX394479B (es) 2025-03-24
CN120754114A (zh) 2025-10-10
JP6901787B2 (ja) 2021-07-14
PE20190380A1 (es) 2019-03-08
WO2017041054A1 (en) 2017-03-09
US20180250264A1 (en) 2018-09-06
CL2018000573A1 (es) 2019-01-11
MX2022009446A (es) 2022-09-05
HK1256480A1 (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
Dolatshahi et al. Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: diverse patterns and mechanisms contributing to neurodegeneration
Wu et al. Anti-inflammatory/Anti-oxidative stress activities and differential regulation of Nrf2-mediated genes by non-polar fractions of tea Chrysanthemum zawadskii and licorice Glycyrrhiza uralensis
Lu et al. Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway
TWI757228B (zh) 含有槲皮素配糖體之筋萎縮抑制劑
Chu Quarter-century explorations of bioactive polyphenols: Diverse health benefits
EP2381935B1 (en) Synergistic combinations of carotenoids and polyphenols
Yang et al. Suppression of LPS‐induced inflammation by chalcone Flavokawain A through activation of Nrf2/ARE‐mediated antioxidant genes and inhibition of ROS/NFκB signaling pathways in primary splenocytes
Wang et al. Recent advances in natural therapeutic approaches for the treatment of cancer
Balstad et al. Coffee, broccoli and spices are strong inducers of electrophile response element‐dependent transcription in vitro and in vivo–Studies in electrophile response element transgenic mice
Xiao et al. Indigo naturalis suppresses colonic oxidative stress and Th1/Th17 responses of DSS‐induced colitis in mice
Zheng et al. Anticancer effect of a curcumin derivative B63: ROS production and mitochondrial dysfunction
Bian et al. Hepatoprotective effect of chiisanoside from Acanthopanax sessiliflorus against LPS/D‐GalN‐induced acute liver injury by inhibiting NF‐κB and activating Nrf2/HO‐1 signaling pathways
Zhang et al. Effects of myricitrin and relevant molecular mechanisms
Xie et al. Comparation of Anti‐Inflammatory and Antioxidantactivities of Curcumin, Tetrahydrocurcuminand Octahydrocurcuminin LPS‐Stimulated RAW264. 7 Macrophages
Soliman et al. Protective Impacts of Moringa oleifera Leaf Extract against Methotrexate‐Induced Oxidative Stress and Apoptosis on Mouse Spleen
Zhang et al. Anticarcinogenic effects of isothiocyanates on hepatocellular carcinoma
Wang et al. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer
Han et al. Ginsenoside Rg1: A Neuroprotective Natural Dammarane‐Type Triterpenoid Saponin With Anti‐Depressive Properties
CN108136209A (zh) 用于改进nrf2激活的组合物和其使用方法
Rayginia et al. Phytochemicals as potential lead molecules against hepatocellular carcinoma
Uzun et al. Sesquiterpenes and prostate cancer
US20260034137A1 (en) Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity
US20100197780A1 (en) Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
Liao et al. Quercetin modulates cytokine expression and inhibits TLR2 expression and STAT3 activation in mouse activated inflammatory macrophages
Masaud et al. Potential of therapeutic antioxidant compounds from pomegranate as anti-cancer agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256480

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180608

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1256480

Country of ref document: HK